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There are several disorders which carry an increased risk of 
thrombosis, clots that interfere with normal circulation, 
including: venous thromboembolism (VTE), comprising both 
deep vein thrombosis (DVT) and pulmonary embolism (PE), 
atrial fibrillation (AF), acute coronary syndromes (ACS), 
valve disease and endocarditis, and conditions associated 
with a raised risk of ischemic stroke. Due to this increased 
risk, a number of thromboprophylactic medications target 
the coagulation cascade. Effective anticoagulation can be 
achieved by inhibiting different coagulation factors in the 
coagulation cascade.
1.1  Overview of the Coagulation Cascade
The coagulation cascade is composed of two pathways; the 
intrinsic, or contact activation pathway and the extrinsic, or 
tissue factor pathway (Fig. 1.1). The main function of the 
coagulation cascade is the formation of an insoluble fibrin 
clot [1]. If a hemorrhage occurs due to blood vessel injury, the 
coagulation system facilitates hemostasis.
A series of reactions occur throughout the coagulation 
cascade causing the conversion of inactive enzyme precursors 
to their active forms; these active forms catalyze the 
 subsequent reactions in the cascade. The coagulation cascade 
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2prevents both excessive bleeding and excessive coagulation 
through a negative feedback loop, self-maintained by a regu-
lated balance of procoagulant and anticoagulant factors.
In the extrinsic (tissue factor) pathway [2, 3] when the 
coagulation cascade is activated tissue factor (TF) is released 
from subendothelial tissue and comes into contact with factor 
VII which, in the presence of Ca2+, forms the activated 
 complex TF-VIIa. TF-VIIa catalyzes the conversion of factor 
X to factor Xa which, along with activated factor V, initiates 





























Figure 1.1 The coagulation cascade
Chapter 1. Introduction
3factors Va and Xa cleave prothrombin fragments 1 and 2. 
Thrombin then cleaves fibrinopeptides A and B from fibrino-
gen resulting in insoluble fibrin.
In the intrinsic (contact activation) pathway [2, 3] damage to 
the endothelial surface causes the formation of factor XIIa 
from factor XII, which in turn triggers formation of factor XIa 
from factor XI. Factor XIa catalyzes the conversion of factor IX 
to factor IXa (in the presence of Ca2+), which triggers the con-
version of factor VIII to factor VIIIa. Factors IXa and VIIIa 
form a catalytic complex and activate factor X. The formation 
of factor Xa marks the convergence of the extrinsic and intrin-
sic pathways into a common pathway, which is responsible for 
the formation of a fibrin mesh on the damaged vessel wall.
1.2  Current Approaches to Anticoagulation
Currently vitamin K antagonists (VKAs), such as warfarin, 
are the mainstay of anticoagulant treatment. VKAs have 
been the oral anticoagulant of choice for more than 50 years, 
with warfarin being the most commonly used VKA world-
wide due to its low cost and once-daily (qd) dosing [4].
Warfarin is highly effective in the prevention of stroke and 
recurrent VTE, showing improved efficacy over antiplatelet 
therapy [5, 6]. Indeed, warfarin has been shown to reduce the 
risk of VTE by ~85 % compared with placebo [5]. Furthermore, 
warfarin has been found to reduce the risk of stroke by 
~62 % (relative risk reduction, 36 % [95 % confidence inter-
val (CI) 14–52 %]), compared with aspirin [6].
Warfarin inhibits the normal production of several antico-
agulation factors that are dependent upon vitamin K [7]. 
When vitamin K is available these anticoagulation factors are 
γ-carboxylated leading to the expression of their procoagula-
tion activity. The availability of vitamin K depends on the 
normal functioning of the enzyme vitamin K epoxide reduc-
tase. Warfarin inhibits this enzyme leading to a lack of vita-
min K resulting in the production of functionally impaired, 
partially carboxylated and decarboxylated factors with cor-
responding anticoagulant effects.
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VKA treatment including: a number of drug and food interac-
tions, individual dose-adjustment based on international normal-
ization ratio (INR), maintenance of INR within the time in 
therapeutic range (TTR), and the need for constant monitoring.
The number of food and drug interactions associated with 
VKA use results in a substantial variability in the absorption 
and bioavailability of warfarin [8]. For example low-dose vita-
min K can reverse the effects of warfarin, whereas high con-
centrations of vitamin K lead to its accumulation in the liver, 
which can make the patient resistant to warfarin [9]. As such, 
foods containing a high concentration of vitamin K (such as 
broccoli) can reduce the effect of warfarin [9]. Additionally, the 
consumption of alcohol can interact with liver enzymes which 
have the potential to affect the metabolism of warfarin. 
Furthermore, it often takes several days to reach therapeutic 
levels due to its long half-life (approx. 40 h). Warfarin is mainly 
bound to albumin in the plasma and metabolized in the liver.
The effectiveness and safety of warfarin are critically 
dependent on maintaining the INR within a therapeutic range 
of 2.0–3.0. Due to the wide number of pharmacological inter-
actions, warfarin requires regular monitoring of its anticoagu-
lant activity and patients require individual dose adjustment.
Treatment with warfarin is associated with a number of 
side-effects, including increased risk of severe hemorrhagic 
complications, such as intracranial hemorrhage. Over- 
anticoagulation (INR >3.0) carries a high risk of intracranial 
hemorrhage, which accounts for ~90 % of deaths from 
warfarin- associated hemorrhage [10]. Furthermore, the 
 benefits of warfarin are only seen in AF patients whose mini-
mum TTR is between 58 and 65 % [11].
1.3  The Ideal Anticoagulant
The limitations described above complicate the use of these 
drugs, especially in the long term setting, and there remains a 
need for anticoagulants that are at least as effective but safer 
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5and more convenient. The development of new anticoagu-
lants has identified a number of properties for an ‘ideal 
anticoagulant’.
The ideal anticoagulant should have a quick onset of 
action that remains stable throughout the day. Additionally, it 
should target specific coagulation factors within the coagula-
tion cascade, preferably acting independently of cofactors, 
with predictable anticoagulant effects, and fixed doses. Ideally, 
only pathological thrombosis leading to thromboembolic 
events would be inhibited, but a certain extension of activity 
of the coagulation system that maintains physiological hemo-
stasis should be allowed [12].
From a clinical perspective, the ideal anticoagulant 
should have easy oral application, a wide therapeutic win-
dow, predictable pharmacodynamic and pharmacokinetic 
properties, and a low risk for interactions with other drugs 
or food, allowing for a simple dosing regimen without the 
need for regular monitoring. Moreover, it would have a 
reversible anticoagulant effect for emergency situations 
and the risk of hemorrhage and effects on other organs 
should be minimal.
A better understanding of the coagulation cascade led 
to identification of many targets for novel anticoagulants 
in the coagulation pathway. Indeed, a number of non-VKA 
oral anticoagulants (NOACs) have been launched or are 
currently in development, which have the potential to 
overcome the limitations associated with VKAs. With the 
use of NOACs, such as direct oral thrombin inhibitors 
(dabigatran) or factor Xa inhibitors (apixaban, rivaroxa-
ban, edoxaban), some of the inherent problems such as 
regular INR monitoring, dose adjustment, and food and 
drug interactions, will be removed.
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